AKT1 and Hepatic fibrosis: It was, therefore, hypothesized that sotagliflozin may have hepatoprotective effects through the modulation of the Sirt1/Nrf2 and PI3K/AKT pathways, causing a decline in oxidative stress, inflammation, and apoptosis in hepatic fibrosis.